Zacks Research Analysts Lift Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Zacks Research upped their Q2 2028 EPS estimates for Iovance Biotherapeutics in a report issued on Friday, June 26th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.06). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.62) per share.

A number of other equities analysts also recently commented on IOVA. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. UBS Group upped their price objective on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Thursday, March 5th. Chardan Capital dropped their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Price Performance

IOVA opened at $3.97 on Thursday. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -4.18 and a beta of 0.74. Iovance Biotherapeutics has a one year low of $1.68 and a one year high of $5.63. The business has a 50 day simple moving average of $3.86 and a two-hundred day simple moving average of $3.40.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $71.43 million during the quarter, compared to analysts’ expectations of $77.84 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm’s revenue for the quarter was up 44.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.36) EPS.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Xponance LLC lifted its position in Iovance Biotherapeutics by 19.4% during the 4th quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 3,950 shares during the period. Raymond James Financial Inc. grew its stake in shares of Iovance Biotherapeutics by 1.4% in the 2nd quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after buying an additional 4,618 shares during the last quarter. Orion Investment Co increased its position in Iovance Biotherapeutics by 0.3% during the 4th quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock valued at $5,069,000 after buying an additional 5,150 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Iovance Biotherapeutics by 37.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,290 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 5,301 shares during the last quarter. Finally, Captrust Financial Advisors boosted its holdings in Iovance Biotherapeutics by 13.5% in the fourth quarter. Captrust Financial Advisors now owns 46,812 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 5,563 shares in the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.